(AOF) – Onxeo shareholders have approved the withdrawal from the Nasdaq First North market in Copenhagen. They conferred full powers on the Board of Directors to carry out this operation. The company will formally request, in the coming days, the delisting of the Nasdaq First North from the Danish stock market operator. After market operator approval, the shares will be effectively delisted from the Nasdaq First North market after an additional 10 weeks.
AOF – LEARN MORE
An inevitable race for new blockbusters
The patent for Merck’s star product, the cancer drug Keytruda, which accounts for more than 35% of its sales, expires in 2028. Despite the loss, since 2019, of the patents for its three star products (Avastin, Herceptine, Rituxan) Roche was able to renew its portfolio by bringing new molecules to market. However, the discovery and launch of new drugs are increasingly expensive. AstraZeneca spends about $6 billion a year on R&D in a pharmaceutical industry where the life of a patent only lasts ten to fifteen years. This leads laboratories to withdraw from certain activities. Thus J&J, Pfizer, GSK and, no doubt, Novartis soon prefer to refocus on specialty drugs and abandon any ancillary activity.